Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.5B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Tesla
TSLA
|
+$951M |
| 4 |
Johnson & Johnson
JNJ
|
+$750M |
| 5 |
UnitedHealth
UNH
|
+$703M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$913M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$257M |
| 3 |
NVIDIA
NVDA
|
+$225M |
| 4 |
Vertiv
VRT
|
+$164M |
| 5 |
JPMorgan Chase
JPM
|
+$161M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.48% |
| 2 | Healthcare | 7.36% |
| 3 | Financials | 6.5% |
| 4 | Consumer Discretionary | 5.35% |
| 5 | Industrials | 3.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4501
Black Diamond Therapeutics
BDTX
$96.8M
| $34.8K | ﹤0.01% |
19,351
-1,584
| -8% | -$2.85K |
|
4502
Atomera
ATOM
$200M
| $34.4K | ﹤0.01% |
5,538
+4,664
| +534% | +$38.2K |
|
|
AE
4503
DELISTED
Adams Resources & Energy Inc
AE
| $34.4K | ﹤0.01% |
885
| – | – |
|
4504
Foghorn Therapeutics
FHTX
$266M
| $34.4K | ﹤0.01% |
5,397
+4,545
| +533% | +$34.3K |
|
4505
Outlook Therapeutics
OTLK
$183M
| $34.4K | ﹤0.01% |
1,590
+1,339
| +533% | +$29.1K |
|
4506
Black Stone Minerals
BSM
$3.18B
| $34.3K | ﹤0.01% |
2,033
-44,455
| -96% | -$787K |
|
|
NREF
4507
NexPoint Real Estate Finance
NREF
$320M
| $34.3K | ﹤0.01% |
2,158
-2,583
| -54% | -$44.5K |
|
|
CAF
4508
Morgan Stanley China A Share Fund
CAF
$322M
| $34.2K | ﹤0.01% |
2,005
| – | – |
|
4509
Nerdy
NRDY
$106M
| $33.7K | ﹤0.01% |
14,989
+12,691
| +552% | +$27.6K |
|
|
NEUE
4510
DELISTED
NeueHealth
NEUE
| $33.7K | ﹤0.01% |
648
+546
| +535% | +$39.7K |
|
4511
Ouster
OUST
$2.63B
| $33.6K | ﹤0.01% |
3,896
+3,290
| +543% | +$35.8K |
|
4512
Weyco Group
WEYS
$372M
| $33.5K | ﹤0.01% |
1,584
+1,334
| +534% | +$32K |
|
4513
StealthGas
GASS
$332M
| $33.5K | ﹤0.01% |
12,500
| – | – |
|
4514
Empire Petroleum
EP
$99.1M
| $33.4K | ﹤0.01% |
2,715
+2,286
| +533% | +$31.8K |
|
4515
Applied Digital
APLD
$7.89B
| $33.4K | ﹤0.01% |
18,140
+17,798
| +5,204% | +$35.1K |
|
|
TGAN
4516
DELISTED
Transphorm, Inc. Common Stock
TGAN
| $33.2K | ﹤0.01% |
6,109
+5,144
| +533% | +$30.3K |
|
|
VXRT
4517
DELISTED
Vaxart
VXRT
| $33.2K | ﹤0.01% |
34,525
-621,592
| -95% | -$878K |
|
4518
UNIFI
UFI
$119M
| $33.1K | ﹤0.01% |
3,847
-97
| -2% | -$834 |
|
4519
Arena Group
AREN
$57.1M
| $33.1K | ﹤0.01% |
3,118
+2,637
| +548% | +$34.2K |
|
|
TCRR
4520
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $33.1K | ﹤0.01% |
33,116
-445
| -1% | -$600 |
|
4521
Relmada Therapeutics
RLMD
$557M
| $32.9K | ﹤0.01% |
9,427
+2,326
| +33% | +$20.4K |
|
4522
Lineage Cell Therapeutics
LCTX
$269M
| $32.9K | ﹤0.01% |
28,109
+20,472
| +268% | +$25.8K |
|
|
RSVR
4523
DELISTED
Reservoir Media
RSVR
| $32.8K | ﹤0.01% |
5,492
+4,625
| +533% | +$26.4K |
|
4524
Immuneering
IMRX
$267M
| $32.8K | ﹤0.01% |
6,758
+2,168
| +47% | +$19.2K |
|
4525
Northeast Community Bancorp
NECB
$368M
| $32.6K | ﹤0.01% |
2,182
+1,671
| +327% | +$23K |
|
Similar funds
Barclays's Q4 2022 Portfolio in Review
As of Q4 2022, Barclays held 5,646 positions worth $223B, up 144% from $91.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $128B of net new capital in Q4 2022, opening 798 new positions and adding to 2,634 existing holdings. Its largest new stake was Seadrill: 1,546,558 shares worth $50.5M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $257M trimmed.
- Barclays's largest Q4 2022 buy was Seadrill: 1,546,558 shares worth $50.5M.
- Barclays added most to Microsoft in Q4 2022, an estimated $2.5B increase.
- Barclays's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $257M.
- Barclays fully exited Citrix Systems Inc in Q4 2022, selling an estimated $913M.
- Barclays's ten largest holdings make up 41% of its $223B portfolio in Q4 2022.
- Barclays opened 798 new positions and closed 385 in Q4 2022.
- Barclays's portfolio value rose 144% quarter-over-quarter to $223B.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.